TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dietary Sodium Reduction in Kidney Disease Patients With Albuminuria
Brief Summary: The proposed randomized controlled trial will test the effect of dietary sodium reduction on albuminuria in patients with proteinuric chronic kidney disease. Results from this study will clarify the role of dietary sodium reduction in management of patients with proteinuric chronic kidney disease and its potential to halt the progression of chronic kidney disease.


Options:
A: Arm Label: Low Salt Diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low Salt Diet | Arm Label: Ususal Salt Diet; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Usual Salt Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low Salt Diet; Assigned to Arm(s): Low Salt Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Usual Salt Diet; Assigned to Arm(s): Ususal Salt Diet
B: Arm Label: Low Sodium Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low Sodium Diet | Arm Label: Usual Diet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low Sodium Diet; Assigned to Arm(s): Low Sodium Diet
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: OxSalt care bundle | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: OxSalt care bundle; Assigned to Arm(s): Intervention
D: Arm Label: Sequence: ABBA A=usual care, B=self-care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BAAB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence AABB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Arm Label: Sequence BBAA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-care management program | Intervention Type: BEHAVIORAL; Name: Self-care management program; Assigned to Arm(s): Sequence AABB, Sequence BAAB, Sequence BBAA, Sequence: ABBA A=usual care, B=self-care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Brief Summary: The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab
C: Arm Label: ECULIZUMAB; Type: OTHER; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): ECULIZUMAB
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PREgnancy-associated Pelvic Floor Health Knowledge And REDuction of Symptoms: The PREPARED Trial
Brief Summary: The pelvic floor is composed of muscles and connective tissue which acts to provide support for pelvic organs, and weakness or injury to the pelvic floor can result in pelvic floor dysfunction. Respect for patient autonomy is a guiding principle in medicine and is of increasing importance for patients. The PREPARED Trial hopes to demonstrate whether a single workshop on pelvic floor health during pregnancy will lead to improved knowledge of pelvic floor symptoms postpartum, increase the practice of pelvic floor muscle exercises, increase satisfaction with their delivery experience, and change participants preferences and thoughts surrounding various modes of delivery.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Workshop; Assigned to Arm(s): Intervention
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise / Physical Activity | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Exercise / Physical Activity; Assigned to Arm(s): Lifestyle intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: A supervised physical exercise program | Intervention Type: BEHAVIORAL; Name: A supervised physical exercise program; Assigned to Arm(s): Exercise group
D: Arm Label: stabilization exercises; Type: EXPERIMENTAL; Interventions: Other: Stabilization exercise | Arm Label: control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: OTHER; Name: Stabilization exercise; Assigned to Arm(s): stabilization exercises | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PREgnancy-associated Pelvic Floor Health Knowledge And REDuction of Symptoms: The PREPARED Trial
Brief Summary: The pelvic floor is composed of muscles and connective tissue which acts to provide support for pelvic organs, and weakness or injury to the pelvic floor can result in pelvic floor dysfunction. Respect for patient autonomy is a guiding principle in medicine and is of increasing importance for patients. The PREPARED Trial hopes to demonstrate whether a single workshop on pelvic floor health during pregnancy will lead to improved knowledge of pelvic floor symptoms postpartum, increase the practice of pelvic floor muscle exercises, increase satisfaction with their delivery experience, and change participants preferences and thoughts surrounding various modes of delivery.


Options:
A: Intervention Type: BEHAVIORAL; Name: Supervised exercise for the prevention high weight gain; Assigned to Arm(s): N/A
B: Arm Label: Postpartum pelvic floor muscle training; Type: EXPERIMENTAL; Interventions: Other: Postpartum pelvic floor muscle training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Postpartum pelvic floor muscle training; Assigned to Arm(s): Postpartum pelvic floor muscle training
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Educational Workshop | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Workshop; Assigned to Arm(s): Intervention
D: Arm Label: G1; Type: EXPERIMENTAL; Interventions: Procedure: Pregnants for receive the physical therapy guide | Intervention Type: PROCEDURE; Name: Pregnants for receive the physical therapy guide; Assigned to Arm(s): G1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjustment Post Stroke and Aphasia: Supporting Psychological Wellbeing Through Peer Befriending
Brief Summary: Aims: This exploratory trial will:

1. Explore the feasibility of a definitive/phase III RCT on clinical and cost-effectiveness of peer-befriending for people with aphasia post-stroke.
2. Investigate psychological and social wellbeing outcomes of participants, significant others, and peer befrienders.
3. Explore the feasibility of a full economic evaluation of usual care + peer befriending versus usual care control.

Design: Single blind, mixed methods, parallel group phase II RCT comparing usual care + peer-befriending vs. usual care, starting at discharge from hospital. The study will deliver on four work packages: development phase; RCT; qualitative study; economic evaluation. Participants (n=60) will be assessed three times up to 10 months post-randomisation.

Outcome measures: Feasibility: feasibility of recruitment to definitive trial (proportion screened who meet criteria; proportion who consent; rate of consent); participant, significant other, peer befriender views on acceptability of procedures (qualitative study); number of missing/incomplete data on outcome measures; attrition rate at follow-up; potential value of conducting main trial using value of information analysis (economic evaluation); description of usual care; treatment fidelity of peer-befriending. Patient-reported outcomes will include mood, wellbeing, communication and social participation.

Benefits: Peer befriending may help avert some of the serious psychological consequences of stroke, and prevent the need for more complex and costly psychological therapies.


Options:
A: Arm Label: Recovering Together; Type: EXPERIMENTAL; Interventions: Behavioral: Recovering Together | Arm Label: Health Education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Recovering Together; Assigned to Arm(s): Recovering Together
B: Arm Label: USUAL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: USUAL | Arm Label: PEER; Type: EXPERIMENTAL; Interventions: Behavioral: PEER, Behavioral: USUAL | Intervention Type: BEHAVIORAL; Name: PEER; Assigned to Arm(s): PEER | Intervention Type: BEHAVIORAL; Name: USUAL; Assigned to Arm(s): PEER, USUAL
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified cognitive behavioral therapy plus problem-solving | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: BEHAVIORAL; Name: Modified cognitive behavioral therapy plus problem-solving; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): 2
D: Arm Label: active rTMS treatment; Type: EXPERIMENTAL; Interventions: Device: active rTMS treatment | Arm Label: sham rTMS treatment; Type: SHAM_COMPARATOR; Interventions: Device: sham rTMS treatment | Intervention Type: DEVICE; Name: active rTMS treatment; Assigned to Arm(s): active rTMS treatment | Intervention Type: DEVICE; Name: sham rTMS treatment; Assigned to Arm(s): sham rTMS treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Time Restricted Feeding for Weight Loss and Cardio-protection
Brief Summary: Time restricted feeding (TRF) is a novel form of intermittent fasting that involves confining the period of food intake to 8 h/d (e.g. 10 am to 6 pm) without calorie counting. TRF is effective for weight loss and cardio-protection in obese adults. It is of great interest to see whether subjects can adhere to TRF for longer periods of time, and to see what degree of weight loss that can be achieved with TRF. Accordingly, the aims of this trial are: Aim 1: To determine if TRF can be implemented to facilitate weight loss in obese adults, and Aim 2: To determine if TRF can produce clinically meaningful reductions in plasma lipids, blood pressure, insulin resistance, and inflammatory markers.


Options:
A: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Alternate Day Fasting Arm; Type: OTHER; Interventions: Behavioral: calorie restriction | Arm Label: Calorie Restriction; Type: OTHER; Interventions: Behavioral: calorie restriction | Intervention Type: BEHAVIORAL; Name: calorie restriction; Assigned to Arm(s): Alternate Day Fasting Arm, Calorie Restriction
C: Arm Label: Time restricted feeding; Type: EXPERIMENTAL; Interventions: Other: Time restricted feeding | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Time restricted feeding; Assigned to Arm(s): Time restricted feeding
D: Arm Label: Normal Diet; Type: PLACEBO_COMPARATOR; Interventions: Other: Resistance Training, Dietary Supplement: Protein Supplementation | Arm Label: Time-Restricted Feeding; Type: EXPERIMENTAL; Interventions: Other: Resistance Training, Dietary Supplement: Protein Supplementation, Behavioral: Time-Restricted Feeding | Arm Label: Time-Restricted Feeding plus HMB; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-hydroxy beta-methylbutyrate, Other: Resistance Training, Dietary Supplement: Protein Supplementation, Behavioral: Time-Restricted Feeding | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-hydroxy beta-methylbutyrate; Assigned to Arm(s): Time-Restricted Feeding plus HMB | Intervention Type: OTHER; Name: Resistance Training; Assigned to Arm(s): Normal Diet, Time-Restricted Feeding, Time-Restricted Feeding plus HMB | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein Supplementation; Assigned to Arm(s): Normal Diet, Time-Restricted Feeding, Time-Restricted Feeding plus HMB | Intervention Type: BEHAVIORAL; Name: Time-Restricted Feeding; Assigned to Arm(s): Time-Restricted Feeding, Time-Restricted Feeding plus HMB

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing mHealth Technology in the PCMH Environment to Activate Chronic Care Patients
Brief Summary: Multi-site feasibility study designed to assist type-2 diabetes patients in self-care activities. The study includes Bluetooth-enabled medical devices (i.e. scales, blood pressure cuffs, glucometers, and activity monitors) for both intervention and control groups. Those in the intervention group will have the devices linked too a mobile health care environment that provides key benefits that include: device data trending, reinforcing tailored behavioral messages, and enhanced communication with the clinic.


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: Intervention to Patients; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Other: Usual care | Arm Label: Intervention to healthcare Professionals; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Mixed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention to patients, Behavioral: Intervention to professionals, Other: Usual care | Arm Label: Control; Type: OTHER; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention to patients; Assigned to Arm(s): Intervention to Patients, Mixed Intervention | Intervention Type: BEHAVIORAL; Name: Intervention to professionals; Assigned to Arm(s): Intervention to healthcare Professionals, Mixed Intervention | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control, Intervention to Patients, Intervention to healthcare Professionals, Mixed Intervention
C: Arm Label: Feedback report only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Goal-Setting Worksheet; Type: EXPERIMENTAL; Interventions: Other: Worksheet to facilitate goal-setting and action plans | Intervention Type: OTHER; Name: Worksheet to facilitate goal-setting and action plans; Assigned to Arm(s): Goal-Setting Worksheet
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Mobile Health Care Environment (MHCE) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Health Care Environment (MHCE); Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.


Options:
A: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Ravulizumab
B: Arm Label: eculizumab; Type: EXPERIMENTAL; Interventions: Drug: eculizumab | Intervention Type: DRUG; Name: eculizumab; Assigned to Arm(s): eculizumab
C: N/A
D: Arm Label: OMS721 low dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 medium dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Arm Label: OMS721 high dose; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721 high dose, OMS721 low dose, OMS721 medium dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Saline Hypertonic in Preschoolers With Cystic Fibrosis and Lung Structure as Measured by Computed Tomography (CT)
Brief Summary: The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks reduces structural lung disease as assessed by computed tomography (CT) in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 6) with cystic fibrosis.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Arm Label: 2; Type: OTHER; Interventions: Drug: rhDNAse, Other: Placebo | Intervention Type: DRUG; Name: rhDNAse; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 1, 2
B: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Active Treatment Group 7% Hypertonic Saline | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control Group 0.9% Isotonic Saline | Intervention Type: DRUG; Name: Active Treatment Group 7% Hypertonic Saline; Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: Control Group 0.9% Isotonic Saline; Assigned to Arm(s): Control Group
C: Arm Label: Pulmozyme; Type: EXPERIMENTAL; Interventions: Drug: Pulmozyme (dornase alfa) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pulmozyme (dornase alfa); Assigned to Arm(s): Pulmozyme | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 7% Hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline | Arm Label: Hypertonic xylitol; Type: EXPERIMENTAL; Interventions: Drug: Xylitol | Intervention Type: DRUG; Name: Xylitol; Assigned to Arm(s): Hypertonic xylitol | Intervention Type: DRUG; Name: Hypertonic saline; Assigned to Arm(s): 7% Hypertonic saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
Brief Summary: The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.


Options:
A: Arm Label: Part 1: ESA-Naïve Participants - Low Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Naïve Participants - Standard Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Treated Participants - Low Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Treated Participants - Standard Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Part 1: ESA-Naïve Participants - Low Weight Based Dosing, Part 1: ESA-Naïve Participants - Standard Weight Based Dosing, Part 1: ESA-Treated Participants - Low Weight Based Dosing, Part 1: ESA-Treated Participants - Standard Weight Based Dosing, Part 2: Roxadustat BIW, Part 2: Roxadustat QW, Part 2: Roxadustat TIW
B: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934)
C: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Iron | Arm Label: ESA (Erythropoiesis Stimulating Agent) treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa, Drug: Darbepoetin alfa, Drug: Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Iron; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment, Roxadustat
D: Arm Label: ASP1517 Group; Type: EXPERIMENTAL; Interventions: Drug: roxadustat | Arm Label: Darbepoetin alfa Group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: roxadustat; Assigned to Arm(s): ASP1517 Group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa Group

Answer: D